Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced additional follow-up ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...

treated with high doses of silymarin (560 mg/day) for 8 weeks. Resolution of subjective symptoms was achieved in 63% of cases; AST diminished on average by 36%, ALT by 34% and GGT by 46%.

Paraneoplastic Syndromes Paraneoplastic syndromes are signs and symptoms caused by hormones ... including aspartate aminotransaminase (AST), alanine aminotransferase (ALT), gamma-glutamyl ...

While it is popularly used to alleviate menopausal symptoms ... high doses of its supplements may elevate liver enzymes like alanine aminotransferase (ALT), aspartate aminotransferase (AST ...

JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...

Within 3 days of taking enoxaparin, elevated transaminases were noted ... Alanine aminotransferase (ALT) was 88 U/L (7–40 U/L), and aspartate aminotransferase (AST) was 59 U/L (12–45 U/L). His direct ...